We are live on ! Find out more
PGNX

Progenics Pharmaceuticals Inc
PGNX

Delisted

PGNX was delisted on the 19th of June, 2020.

Back to rankings

76 hedge funds and large institutions have $219M invested in Progenics Pharmaceuticals Inc in 2014 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 28 increasing their positions, 25 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

21% more call options, than puts

Call options by funds: $948K | Put options by funds: $781K

12% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 25

3% more capital invested

Capital invested by funds: $213M → $219M (+$5.72M)

13% less funds holding

Funds holding: 87 → 76 (-11)

55% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 20

Holders
76
Holders Change
-11
Holders Change %
-12.64%
% of All Funds
2.18%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.03%
New
9
Increased
28
Reduced
25
Closed
20
Calls
$948K
Puts
$781K
Net Calls
+$167K
Net Calls Change
+$123K

Top Buyers

Rank Fund Capital Flow
1
BC
Broadfin Capital
New York
+$4.01M
2
HCMT
Highland Capital Management (Texas)
Texas
+$785K
3
Millennium Management
Millennium Management
New York
+$505K
4
JG
Jefferies Group
New York
+$496K
5
PFC
Phocas Financial Corp
California
+$482K

Top Sellers

Rank Fund Capital Flow
1
TCA
Taconic Capital Advisors
New York
-$3.21M
2
Franklin Resources
Franklin Resources
California
-$2.6M
3
NI
Numeric Investors
Massachusetts
-$1.46M
4
Fidelity Investments
Fidelity Investments
Massachusetts
-$1.26M
5
HCM
Highbridge Capital Management
New York
-$708K
Name Holding Trade Value Shares
Change 		Change in
Stake
Federated Hermes
1
Federated Hermes
Pennsylvania
$58.2M -$158K -41,500 -0.3%
BC
2
Broadfin Capital
New York
$28.6M +$4.01M +1,050,000 +19%
BBA
3
Baker Bros. Advisors
New York
$19.2M – – –
Fidelity Investments
4
Fidelity Investments
Massachusetts
$17.6M -$1.26M -329,900 -7%
BFA
5
BlackRock Fund Advisors
California
$11.2M -$636K -166,489 -6%
BIT
6
BlackRock Institutional Trust
California
$10.3M +$133K +34,784 +1%
Tudor Investment Corp
7
Tudor Investment Corp
Connecticut
$10.1M – – –
Vanguard Group
8
Vanguard Group
Pennsylvania
$8.28M +$251K +65,664 +4%
HCMT
9
Highland Capital Management (Texas)
Texas
$6.85M +$785K +205,634 +15%
Wellington Management Group
10
Wellington Management Group
Massachusetts
$6.76M +$89.7K +23,490 +2%
State Street
11
State Street
Massachusetts
$4.29M +$5.81K +1,522 +0.2%
PFC
12
Phocas Financial Corp
California
$4.02M +$482K +126,285 +16%
Morgan Stanley
13
Morgan Stanley
New York
$3.67M +$336K +87,978 +12%
Northern Trust
14
Northern Trust
Illinois
$3.32M -$74.7K -19,555 -2%
Dimensional Fund Advisors
15
Dimensional Fund Advisors
Texas
$2.94M -$100K -26,218 -4%
Fuller & Thaler Asset Management
16
Fuller & Thaler Asset Management
California
$2.41M +$204K +53,500 +11%
Geode Capital Management
17
Geode Capital Management
Massachusetts
$1.78M +$5.29K +1,386 +0.3%
SM
18
Sabby Management
Florida
$1.57M -$583K -152,608 -29%
Bank of New York Mellon
19
Bank of New York Mellon
New York
$1.42M -$118K -30,968 -9%
TCIM
20
TIAA CREF Investment Management
New York
$1.31M +$304K +79,505 +35%
California Public Employees Retirement System
21
California Public Employees Retirement System
California
$1.25M – – –
WAM
22
Wolverine Asset Management
Illinois
$1.03M +$192K +50,400 +27%
Deutsche Bank
23
Deutsche Bank
Germany
$1.01M -$99.7K -26,113 -10%
BIM
24
BlackRock Investment Management
Delaware
$959K +$92.3K +24,173 +12%
AIG
25
American International Group
New York
$751K +$68.4K +17,903 +11%
1
2 3 4

PGNX Hedge Fund Activity: Q2 2014 in Review

76 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Progenics Pharmaceuticals Inc (PGNX) for Q2 2014, worth a combined $219M — up 2.7% from $213M a quarter earlier.

Sellers outnumbered buyers: 20 funds closed out of PGNX and 9 opened new positions — a net loss of 11 holders — while 25 trimmed existing stakes and 28 added.

The largest buyer was Broadfin Capital, adding an estimated $4.01M. The largest seller was Taconic Capital Advisors, exiting entirely with an estimated $3.21M sold.

  • 76 institutional investors held Progenics Pharmaceuticals Inc (PGNX) as of Q2 2014, down from 87 in Q1 2014.
  • Funds reported $219M of Progenics Pharmaceuticals Inc stock for Q2 2014, up 2.7% quarter-over-quarter.
  • 9 funds opened new Progenics Pharmaceuticals Inc positions in Q2 2014 and 20 closed out, a net change of -11 holders.
  • The largest Progenics Pharmaceuticals Inc buyer in Q2 2014 was Broadfin Capital, an estimated $4.01M added.
  • The largest Progenics Pharmaceuticals Inc seller in Q2 2014 was Taconic Capital Advisors, an estimated $3.21M sold.

Based on aggregated 13F filings for Q2 2014.